CoChat

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

Open access
Lantero‐Rodriguez, Juan, Snellman, Anniina, Benedet, Andrea L, Milà‐Alomà, Marta, Camporesi, Elena, Montoliu‐Gaya, Laia, Ashton, Nicholas J, Vrillon, Agathe, Karikari, Thomas K, Gispert, Juan Domingo, Salvadó, Gemma, Shekari, Mahnaz, Toomey, Christina E, Lashley, Tammaryn L, Zetterberg, Henrik, Suárez‐Calvet, Marc, Brinkmalm, Gunnar, Rosa Neto, Pedro, Blennow, Kaj · 2021 · EMBO Molecular Medicine
Cited by 56

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p-tau) species such as p-tau217 and p-tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression during preclinical AD are still needed. Combining exploratory and targeted mass spectrometry methods in neuropathologically confirmed brain tissue, we observed that p-tau235 is a prominent feature of AD pathology. In addition, p-tau235 seemed to be preceded by p-tau231, in what appeared to be a sequential phosphorylation event. To exploit its biomarker potential in cerebrospinal fluid (CSF), we developed and validated a new p-tau235 Simoa assay. Using three clinical cohorts, we demonstrated that (i) CSF p-235 increases early in AD continuum, and (ii) changes in CSF p-tau235 and p-tau231 levels during preclinical AD are consistent with the sequential phosphorylation evidence in AD brain. In conclusion, CSF p-tau235 appears to be not only a highly specific biomarker of AD but also a promising staging biomarker for the preclinical phase. Thus, it could prove useful tracking disease progression and help enriching clinical trial recruitment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.202115098

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 56

Metadata

Authors
Lantero‐Rodriguez, J., Snellman, A., Benedet, A. L., Milà‐Alomà, M., Camporesi, E., Montoliu‐Gaya, L., Ashton, N. J., Vrillon, A., Karikari, T. K., Gispert, J. D., Salvadó, G., Shekari, M., Toomey, C. E., Lashley, T. L., Zetterberg, H., Suárez‐Calvet, M., Brinkmalm, G., Rosa Neto, P., & Blennow, K.
Venue
EMBO Molecular Medicine
Published
2021-11-02
Volume
13
Issue
12
Pages
e15098-e15098
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W3210306469
Cited by
56
References
29
FWCI
5.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease. https://app.cochat.ai/papers/10.15252/emmm.202115098
The paper
Lantero‐Rodriguez, J., Snellman, A., Benedet, A. L., Milà‐Alomà, M., Camporesi, E., Montoliu‐Gaya, L., Ashton, N. J., Vrillon, A., Karikari, T. K., Gispert, J. D., Salvadó, G., Shekari, M., Toomey, C. E., Lashley, T. L., Zetterberg, H., Suárez‐Calvet, M., Brinkmalm, G., Rosa Neto, P., & Blennow, K. (2021). P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202115098

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.